Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
sensimed.ch

See what CB Insights has to offer

Executives

5

Board of Directors

1

Sensimed Board of Director

1 Board of directors

Sensimed has 1 board of directors, including Erich Schlick.

Name

Firm

Work History

Other Seats

Erich Schlick

Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody. Erich joined Wellington as an Investment Partner for Life Sciences in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.

Name

Erich Schlick

Firm

Work History

Erich Schlick is one of a very few European scientists/drug developers to see their innovation become a blockbuster. This happened in the 1990s when he initiated the development of Humira, the first fully human therapeutic monoclonal antibody. Erich joined Wellington as an Investment Partner for Life Sciences in October 2005. Before this, he served as Director and Head of 3i Healthcare Germany and as Deputy Sector Head 3i Healthcare Worldwide and was responsible for numerous successful investments. Prior to venture capital, Erich spent 15 years with BASF Pharma Knoll AG, 10 years thereof as an executive board member with worldwide responsibility for preclinical and clinical R&D. During this time, he obtained worldwide registrations for five products in cardiovascular, metabolic and pain indications. In 1993, he established the partnership with Cambridge Antibody Technology (CAT), which led to the successful development of Humira. Erich studied medicine and specialised in pharmacology. He holds a professorship of immunopharmacology at the University of Heidelberg/Mannheim.

Other Seats

Sensimed Management Team

5 Team Members

Sensimed has 5 executives. Sensimed's current Chief Executive Officer is Jean-Marc Wismer.

Name

Work History

Title

Status

Jean-Marc Wismer

Chief Executive Officer

Current

Matteo Leonardi

Chief Technology Officer

Current

Rene Goedkoop

Chief Medical Officer

Current

Sacha Cerboni

Controller

Current

Jean Marc Wismer

Founder, Chief Executive Officer

Former

Name

Jean-Marc Wismer

Matteo Leonardi

Rene Goedkoop

Sacha Cerboni

Jean Marc Wismer

Work History

Title

Chief Executive Officer

Chief Technology Officer

Chief Medical Officer

Controller

Founder, Chief Executive Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.